Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells

  • Cánovas, Verónica|||0000-0002-1994-5763
  • Puñal, Yolanda
  • Maggio, Valentina|||0000-0002-4985-5611
  • Redondo, Enric
  • Marín Aguilera, Mercedes
  • Mellado, Begoña|||0000-0002-8088-5966
  • Olivan, Mireia|||0000-0002-8464-0827
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paciucci, Rosanna|||0000-0001-5651-5933
Metastatic prostate cancer is presently incurable. The oncogenic protein PTOV1, first described in prostate cancer, was reported as overexpressed and significantly correlated with poor survival in numerous tumors. Here, we investigated the role of PTOV1 in prostate cancer survival to docetaxel and self-renewal ability. Transduction of PTOV1 in docetaxel-sensitive Du145 and PC3 cells significantly increased cell survival after docetaxel exposure and induced docetaxel-resistance genes expression (ABCB1, CCNG2 and TUBB2B). In addition, PTOV1 induced prostatospheres formation and self-renewal genes expression (ALDH1A1, LIN28A, MYC and NANOG). In contrast, Du145 and PC3 cells knockdown for PTOV1 significantly accumulated in the G2/M phase, presented a concomitant increased subG1 peak, and cell death by apoptosis. These effects were enhanced in docetaxel-resistant cells. Analyses of tumor datasets show that PTOV1 expression significantly correlated with prostate tumor grade, drug resistance (CCNG2) and self-renewal (ALDH1A1, MYC) markers. These genes are concurrently overexpressed in most metastatic lesions. Metastases also show PTOV1 genomic amplification in significant co-occurrence with docetaxel-resistance and self-renewal genes. Our findings identify PTOV1 as a promoter of docetaxel-resistance and self-renewal characteristics for castration resistant prostate cancer. The concomitant increased expression of PTOV1, ALDH1A1 and CCNG2 in primary tumors, may predict metastasis and bad prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Conteduca, Vincenza|||0000-0002-6921-714X
  • Jayaram, Anuradha
  • Romero-Laorden, Nuria
  • Wetterskog, Daniel
  • Salvi, Samanta|||0000-0002-9584-3021
  • Gurioli, Giorgia
  • Scarpi, Emanuela
  • Castro, Elena|||0000-0002-3691-6454
  • Marín Aguilera, Mercedes
  • Lolli, Cristian
  • Schepisi, Giuseppe
  • Maugeri, Antonio
  • Wingate, Anna
  • Farolfi, Alberto
  • Casadio, Valentina
  • Medina, Ana
  • Puente, J.|||0000-0002-6910-1331
  • Vidal, Mª José Méndez
  • Morales-Barrera, Rafael|||0000-0001-7398-0685
  • Villa-Guzmán, Jose C.
  • Hernando-Polo, Susana
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • González-del-Alba, Aránzazu|||0000-0001-6570-009X
  • Mellado, Begoña|||0000-0002-8088-5966
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
  • Olmos, David
  • Attard, Gerhardt
  • De Giorgi, Ugo|||0000-0001-7520-2908
Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR] = 1.61, 95% confidence interval [CI] = 1.08-2.39, p = 0.018), but not PFS (HR = 1.04, 95% CI 0.74-1.46, p = 0.8) or PSA response (odds ratio = 1.14, 95% CI = 0.65-1.99, p = 0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR = 0.16, 95% CI = 0.06-0.46, p < 0.001) and PFS (HR = 0.31, 95% CI = 0.12-0.80, p = 0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR -normal patients (HR = 1.93, 95% CI = 1.19-3.12, p = 0.008) and a suggestion favoring docetaxel for AR -gained patients (HR = 0.53, 95% CI = 0.24-1.16, p = 0.11). These data suggest that AR -normal patients should receive abiraterone/enzalutamide and AR -gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR -gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker. Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer

  • Jiménez, Natalia|||0000-0002-7057-0426
  • Reig, Oscar|||0000-0003-1166-6943
  • Montalbo, Ruth
  • Milà-Guasch, Maria
  • Nadal-Dieste, Lluis
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Lozano, Juan José
  • Victoria, Iván
  • Font, Albert|||0000-0003-3908-1111
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Carles, Joan|||0000-0002-9983-5934
  • Suárez, Cristina|||0000-0002-0502-5528
  • Domènech, Montserrat|||0000-0003-3973-0986
  • Sala-González, Núria
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Rodríguez-Carunchio, Leonardo|||0000-0002-7019-554X
  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Prat, Aleix|||0000-0003-2377-540X
  • Marín Aguilera, Mercedes
  • Mellado, Begoña|||0000-0002-8088-5966
The prostatic tumor cells plasticity is involved in resistance to hormone-therapy, allowing these cells to survive despite androgen receptor inhibition. However, its role in taxanes resistance has not been fully established. Gene expression of plasticity-related phenotypes such as epithelial-mesenchymal transition (EMT), stem cell-like and neuroendocrine (NE) phenotypes was studied in vitro, in silico, in circulating tumor cells (CTCs) (N =22) and in tumor samples (N.